119 related articles for article (PubMed ID: 24989481)
1. Predicted ligands for the human urotensin-II G protein-coupled receptor with some experimental validation.
Kim SK; Goddard WA; Yi KY; Lee BH; Lim CJ; Trzaskowski B
ChemMedChem; 2014 Aug; 9(8):1732-43. PubMed ID: 24989481
[TBL] [Abstract][Full Text] [Related]
2. Prediction of the three-dimensional structure for the rat urotensin II receptor, and comparison of the antagonist binding sites and binding selectivity between human and rat receptors from atomistic simulations.
Kim SK; Li Y; Park C; Abrol R; Goddard WA
ChemMedChem; 2010 Sep; 5(9):1594-608. PubMed ID: 20683923
[TBL] [Abstract][Full Text] [Related]
3. Three-dimensional model of the human urotensin-II receptor: docking of human urotensin-II and nonpeptide antagonists in the binding site and comparison with an antagonist pharmacophore model.
Lescot E; Sopkova-de Oliveira Santos J; Colloc'h N; Rodrigo J; Milazzo-Segalas I; Bureau R; Rault S
Proteins; 2008 Oct; 73(1):173-84. PubMed ID: 18409194
[TBL] [Abstract][Full Text] [Related]
4. Pharmacology of the urotensin-II receptor antagonist palosuran (ACT-058362; 1-[2-(4-benzyl-4-hydroxy-piperidin-1-yl)-ethyl]-3-(2-methyl-quinolin-4-yl)-urea sulfate salt): first demonstration of a pathophysiological role of the urotensin System.
Clozel M; Binkert C; Birker-Robaczewska M; Boukhadra C; Ding SS; Fischli W; Hess P; Mathys B; Morrison K; Müller C; Müller C; Nayler O; Qiu C; Rey M; Scherz MW; Velker J; Weller T; Xi JF; Ziltener P
J Pharmacol Exp Ther; 2004 Oct; 311(1):204-12. PubMed ID: 15146030
[TBL] [Abstract][Full Text] [Related]
5. Nonpeptide Urotensin-II receptor agonists and antagonists: review and structure-activity relationships.
Lescot E; Bureau R; Rault S
Peptides; 2008 May; 29(5):680-90. PubMed ID: 18022732
[TBL] [Abstract][Full Text] [Related]
6. Synthesis and SAR of thieno[3,2-b]pyridinyl urea derivatives as urotensin-II receptor antagonists.
Lim CJ; Oh SA; Lee BH; Oh KS; Yi KY
Bioorg Med Chem Lett; 2014 Dec; 24(24):5832-5835. PubMed ID: 25452001
[TBL] [Abstract][Full Text] [Related]
7. The predicted ensemble of low-energy conformations of human somatostatin receptor subtype 5 and the binding of antagonists.
Dong SS; Abrol R; Goddard WA
ChemMedChem; 2015 Apr; 10(4):650-61. PubMed ID: 25772628
[TBL] [Abstract][Full Text] [Related]
8. Combination of Docking-Based and Pharmacophore-Based Virtual Screening Identifies Novel Agonists That Target the Urotensin Receptor.
Li N; Yin L; Chen X; Shang J; Liang M; Gao L; Qiang G; Xia J; Du G; Yang X
Molecules; 2022 Dec; 27(24):. PubMed ID: 36557826
[TBL] [Abstract][Full Text] [Related]
9. Application of Monte Carlo-based receptor ensemble docking to virtual screening for GPCR ligands.
Vilar S; Costanzi S
Methods Enzymol; 2013; 522():263-78. PubMed ID: 23374190
[TBL] [Abstract][Full Text] [Related]
10. Predicted structures for kappa opioid G-protein coupled receptor bound to selective agonists.
Li Q; Kim SK; Goddard WA; Chen G; Tan H
J Chem Inf Model; 2015 Mar; 55(3):614-27. PubMed ID: 25642595
[TBL] [Abstract][Full Text] [Related]
11. Identification of nonpeptidic urotensin II receptor antagonists by virtual screening based on a pharmacophore model derived from structure-activity relationships and nuclear magnetic resonance studies on urotensin II.
Flohr S; Kurz M; Kostenis E; Brkovich A; Fournier A; Klabunde T
J Med Chem; 2002 Apr; 45(9):1799-805. PubMed ID: 11960491
[TBL] [Abstract][Full Text] [Related]
12. Predicted structures of agonist and antagonist bound complexes of adenosine A3 receptor.
Kim SK; Riley L; Abrol R; Jacobson KA; Goddard WA
Proteins; 2011 Jun; 79(6):1878-97. PubMed ID: 21488099
[TBL] [Abstract][Full Text] [Related]
13. Comparing Class A GPCRs to bitter taste receptors: Structural motifs, ligand interactions and agonist-to-antagonist ratios.
Di Pizio A; Levit A; Slutzki M; Behrens M; Karaman R; Niv MY
Methods Cell Biol; 2016; 132():401-27. PubMed ID: 26928553
[TBL] [Abstract][Full Text] [Related]
14. Virtual screening of biogenic amine-binding G-protein coupled receptors: comparative evaluation of protein- and ligand-based virtual screening protocols.
Evers A; Hessler G; Matter H; Klabunde T
J Med Chem; 2005 Aug; 48(17):5448-65. PubMed ID: 16107144
[TBL] [Abstract][Full Text] [Related]
15. Assessment and challenges of ligand docking into comparative models of G-protein coupled receptors.
Nguyen ED; Norn C; Frimurer TM; Meiler J
PLoS One; 2013; 8(7):e67302. PubMed ID: 23844000
[TBL] [Abstract][Full Text] [Related]
16. Discovery of potent and novel smoothened antagonists via structure-based virtual screening and biological assays.
Lu W; Zhang D; Ma H; Tian S; Zheng J; Wang Q; Luo L; Zhang X
Eur J Med Chem; 2018 Jul; 155():34-48. PubMed ID: 29857275
[TBL] [Abstract][Full Text] [Related]
17. In silico studies and fluorescence binding assays of potential anti-prion compounds reveal an important binding site for prion inhibition from PrP(C) to PrP(Sc).
Pagadala NS; Perez-Pineiro R; Wishart DS; Tuszynski JA
Eur J Med Chem; 2015 Feb; 91():118-31. PubMed ID: 25042003
[TBL] [Abstract][Full Text] [Related]
18. Structure-Based Prediction of G-Protein-Coupled Receptor Ligand Function: A β-Adrenoceptor Case Study.
Kooistra AJ; Leurs R; de Esch IJ; de Graaf C
J Chem Inf Model; 2015 May; 55(5):1045-61. PubMed ID: 25848966
[TBL] [Abstract][Full Text] [Related]
19. Identification of potential dual agonists of FXR and TGR5 using e-pharmacophore based virtual screening.
Sindhu T; Srinivasan P
Mol Biosyst; 2015 May; 11(5):1305-18. PubMed ID: 25787676
[TBL] [Abstract][Full Text] [Related]
20. Function-specific virtual screening for GPCR ligands using a combined scoring method.
Kooistra AJ; Vischer HF; McNaught-Flores D; Leurs R; de Esch IJ; de Graaf C
Sci Rep; 2016 Jun; 6():28288. PubMed ID: 27339552
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
